NIFDS seeking to ensure bioequivalence of generic drugs

The National Institute of Food and Drug Safety Evaluation (NIFDS) plans to introduce a regulation that a generic drug manufacturers must provide a full description of the bioequivalence testing results related to a generic product, such as pharmacokinetic profiles (AUC and Cmax), to ensure the firm can manufacture a generic product consistently

In a local scientific convention last Friday, t...